Biotech
Page 1 of 38
- Pfizer Employees Brace Themselves
- Cougar Biotechnology: Stalking Prostate Cancer
- Teva Granted Final Approval of Risperidone ANDA; Launches with 180-Day Exclusivity
- Is 3SBio Too Conservative to Move Forward?
- What's the Story on Amgen Shorts?
- Myriad Genetics: I Told You So
- Pfizer Cuts Costs by Outsourcing Drug Distribution in China
- Sinovac Starts Phase II Trial of Pandemic Flu Vaccine
- AMAG's Iron Replacement Therapy: Great Potential, Problematic Trial
- AstraZeneca's Acquisition of MedImmune Still Looks Overpriced
- Melnyk's Actions Will Only 'Delay the Inevitable' at Biovail
- China Biotech in Review: A Week of Collaborations
- Isis Pharmaceuticals' Obesity Buster an Enormous Finding
- FDA Denies King Pharma's Citizen Petition on Altace; Approves Ramipril ANDAs
- BioMarin, Myriad, and Regeneron Show a Quiet Strength
- Genentech: Britain's National Health Won't Pay for Avastin
- Limited Investment Opportunities in Indian Pharmaceutical Services
- Poniard Pharmaceuticals: Platinum Rediscovered (Part II)
- Amylin Has Yet to Crack Tough Diabetes Market
- Generex Biotechnology and the USMCI: Armed with Antigens in the War Against Breast Cancer
- An Interview With Cleveland BioLabs CEO Michael Fonstein
- FDA Stings Pharma, Big and Small
- Cangene: Canada's Answer to Bioterrorism
- ChinaBio Week in Review: News from the BIO Convention
- Mannkind: Overlooked Biotech With Excellent Prospects (Part VI)
- Potential BioMS: Successful Drug Trials but Risk Still Exists
- Delcath Systems to Take on Onyx Pharma's Nexavar
- Elan, Wyeth: Response to Skeptics on Alzheimer's Data
- Accentia Biopharmaceutical's Multiple Sclerosis Breakthrough
- Mannkind: Overlooked Biotech With Excellent Prospects (Part V)
- TEVA: Breakthrough in Treatment of Parkinson's Disease
- Glaxosmithkline's Weight-Loss Drug Disappoints as Expected
- Bioterrorism: Anthrax and Biotech Companies
- Mannkind: Overlooked Biotech With Excellent Prospects (Part IV)
- Elan, Wyeth Take an Inside-Out Approach to Alzheimer's Vaccine
- Mannkind: Overlooked Biotech With Excellent Prospects (Part III)
- Biotech Fundamentals Still Look Strong
- GlaxoSmithKline's Cutbacks Should Come as No Surprise
- Mylan Prevails Over AstraZeneca in Appeal of Prilosec Case
- Is Pfizer's 7% Dividend Safe?
- Wyeth and Elan Face Big Test on Alzheimer's Drug
- Dendreon's Provenge: Government Agencies Play Hide and Seek With Facts
- Mannkind: Overlooked Biotech With Excellent Prospects (Part II)
- Is Lilly and Amylin's Byetta Better?
- WuXi PharmaTech Signs on for Three More Years with AstraZeneca
July 03, 2008
| Last Updated
18:36
ET
Symbols:
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
Biotech Transcripts
- Repligen Corporation F4Q08 (Qtr End 03/31/2008) Earnings Call Transcript
- China Medical F4Q07 (Qtr End 3/31/08) Earnings Call Transcript
- Oculus Innovative Sciences, Inc. F4Q08 (Qtr End 03/31/08) Earnings Call Transcript
- Zila, Inc. F3Q08 (Qtr End 04/30/2008) Earnings Call Transcript
- Alfacell Corporation F3Q08 (Qtr End 04/30/2008) Earnings Call Transcript
- Enzo Biochem, Inc. F3Q08 (Qtr End 4/30/08) Earnings Call Transcript
- Martek Biosciences Corporation F2Q08 (Qtr End 04/30/2008) Earnings Call Transcript
- Par Pharmaceutical Companies Inc. Q1 2008 Earnings Call Transcript
- Par Pharmaceutical Companies Inc. Q1 2008 Earnings Call Transcript
- Thoratec Corp. Q1 2008 Earnings Call Transcript
Most Popular Feeds
-
ETFs
-
US Market
-
Long Ideas
-
Alt. Energy
- Full list of feeds »
-
Editor's Picks
-
Most Popular
- Assurant Is A Compelling Short Sell
- Broadcom Enters FTTH Chipset Market
- Another Macroshares Oil Arbitrage Opportunity
- Freeport McMoran: With Copper Prices Rising, It's Still a Buy
- Oil and the Futures Market
- Three Ways to Cash In on Record Meat and Dairy Prices
- Full list of Editor's Picks »
- High Likelihood of a Market Crash »
- Time To Start Buying Some Dogs? »
- Sirius-XM Combination: A Future Microsoft Acquisition? »
- JP Morgan Offer for Wachovia Makes Sense »
- Adding to My GE Position »
- High-Yield Canadian Royalty Trusts: What's the Catch? »
- 7 Stocks for a High Yield Cash Flow Portfolio »
- Nokia: Bargain of a Lifetime - Barron's »
- Wall Street Breakfast: Must-Know News »
- Top 10 Payout Yield Stocks »
- Valuing GE (It's Cheap) »
Biotech Comments